Other languages Savara Inc.

Equities

SVRA

US8051111016

Real-time Estimate Cboe BZX Other stock markets 15:14:07 14/05/2024 BST			5-day change	1st Jan Change
4.725 ^USD	+2.94%		-10.08%	+0.64%

05-09	Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	04-12
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024	04-08
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing	12-29
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing	12-29
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis	12-21
Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Savara Prices $80 Million Brokered Offering of Common Shares, Warrants	13/07/23
Savara Completes Enrolment in Study of Molgramostim to Treat Autoimmune Pulmonary Alveolar Proteinosis	26/06/23
Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis	26/06/23
Insider Buy: Savara	26/05/23
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	30/03/23
Savara Appoints Rob Lutz Chief Operating Officer	14/02/23
Savara Inc. Announces New Leadership Appointments	14/02/23
Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Savara Inc.

Equities

SVRA

US8051111016

Other languages

Filters